RegenxBio: Zolgensma revenues disappoint

 Revenues: Revenues were $26.5 million for the three months ended September 30, 2022, compared to $30.8 million for the three months ended September 30, 2021. The decrease was primarily attributable to Zolgensma royalty revenues, which decreased from $30.3 million for the third quarter of 2021 to $25.2 million for the third quarter of 2022. Zolgensma royalty revenues for the nine months ended September 30, 2022 were $75.1 million for the nine months ended September 30, 2022, compared to $66.9 million for the nine months ended September 30, 2021.

https://www.biospace.com/article/releases/regenxbio-reports-third-quarter-2022-financial-results-and-recent-operational-highlights/?keywords=regenxbio